XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.25.3

Financial Instruments | 9 Months Ended
--- | ---
Sep. 30, 2025
Investments, All Other Investments [Abstract] |
Financial Instruments | Note 9. Financial Instruments Cash, Note payable, related party The following tables show the Company’s cash, cash equivalents, restricted cash, and note payable, related party by significant investment category as of: Schedule of Cash, Cash Equivalents, Restricted Cash, and Note Payable Related Party by Significant Investment Category
|  | September 30, 2025 |
|  | Adjusted Cost |  |  | Unrealized (Gain)/Loss |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Note Payable, Related Party |
Level 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 12,000 |  |  | $ | - |  |  | $ | 12,000 |  |  | $ | 12,000 |  |  | $ | - |
Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Note payable, related party |  |  | 14,738,000 |  |  |  | 8,143,000 |  |  |  | 22,881,000 |  |  |  | - |  |  |  | 22,881,000 |
Total |  | $ | 14,750,000 |  |  | $ | 8,143,000 |  |  | $ | 22,893,000 |  |  | $ | 12,000 |  |  | $ | 22,881,000 |
|  | December 31, 2024 |
|  | Adjusted Cost |  |  | Unrealized (Gain)/Loss |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Note Payable, Related Party |
Level 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 1,999,000 |  |  | $ | - |  |  | $ | 1,999,000 |  |  | $ | 1,999,000 |  |  | $ | - |
Level 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Note payable, related party |  |  | 13,946,000 |  |  |  | (5,068,000 | ) |  |  | 8,878,000 |  |  |  | - |  |  |  | 8,878,000 |
Total |  | $ | 15,945,000 |  |  | $ | (5,068,000 | ) |  | $ | 10,877,000 |  |  | $ | 1,999,000 |  |  | $ | 8,878,000 |
Impact Biomedical, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration